Drug Profile

VHX 896

Alternative Names: BysantiTM; Milsaperidone; P-88; VHX-896

Latest Information Update: 11 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vanda Pharmaceuticals
Class Antipsychotics; Mood stabilisers
Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration Bipolar disorders; Schizophrenia
No development reported Psychiatric disorders

Most Recent Events

31 Mar 2025 Preregistration for Bipolar disorders in USA (PO)
31 Mar 2025 Preregistration for Schizophrenia in USA (PO)
28 Feb 2025 Vanda Pharmaceuticals plans a phase III trial for Major depressive disorder (Adjunctive therapy) (PO) in February 2025 (NCT06830044)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com